Real-Time Oncology Review Pilot Program
OCE Real-Time Oncology Review
Related Articles
Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma
PURPOSEAcral lentiginous melanoma is a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin. These tumors are characterized by aggressive biology, a low…
Clinical Implications of a Large-Scale Voluntary Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary Results | JCO Oncology Practice
PURPOSETo assess the impact and outcomes of a novel program for routine preemptive DPYD testing in fluoropyrimidine (FP)-naïve patients.PATIENTS AND METHODSThis single-center, retrospective cohort study…
Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare Cancers | JCO Oncology Practice
In the current evolving landscape of cancer treatment, the notion that all patients with advanced cancer, but especially those with rare cancers, must receive comprehensive…
Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis
Universal germline and tumor genomic testing needed to win the war against cancer.
Universal Genomic Testing Needed to Win the War Against Cancer
This Viewpoint argues for universal tumor sequencing.
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras
The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the…
Whole genome sequencing-powered ctDNA sequencing for breast cancer detection
Circulating tumour DNA (ctDNA)-based detection of molecular residual disease (MRD) presents a strategy to identify patients at high risk of relapse. In this article, we…
panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2-activating mutations.
TPS3185Background: Human epidermal growth factor receptor 2 (HER2) gene mutations occur in approximately 3.5% of solid tumors, with a frequency varying from less than 1%…
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma | NEJM
Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options…
panSOHO: Phase II trial of BAY 2927088 in patients with unresectable or metastatic solid tumors other than NSCLC with HER2-activating mutations.
TPS3185Background: Human epidermal growth factor receptor 2 (HER2) gene mutations occur in approximately 3.5% of solid tumors, with a frequency varying from less than 1%…